Physician profile
Katie E Vance
NPI 1861831869
$5,213.42
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,051 · 2022: $132 · 2023: $17.10 · 2024: $12.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,264.82 | 2021 | |
| Amgen INC. | $303.17 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $236.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $188.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $162.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $139.63 | 2021-2022 | |
| Esperion Therapeutics, INC. | $137.56 | 2021 | |
| Pfizer INC. | $117.36 | 2021 | |
| Amarin Pharma, INC. | $104.71 | 2021 | |
| Boston Scientific Corporation | $93.09 | 2021 | |
| Daiichi Sankyo INC. | $64.74 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $59.33 | 2021 | |
| Elutia, INC. | $41.02 | 2022-2024 | Ecm Patch,Pouch |
| Actelion Pharmaceuticals US, INC. | $34.26 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.14 | 2021 | |
| Bard Peripheral Vascular, INC. | $18.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.